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Purpose: The aim of this study was to evaluate whether low-dose anticholinergics com-
bined with an α1-receptor antagonist would continue the effect of an alpha-blocker, de-
crease the side effects of anticholinergics, and improve the symptoms of lower urinary 
tract symptoms/benign prostatic hyperplasia (LUTS/BPH).
Materials and Methods: Two hundred nine men with LUTS/BPH with storage symp-
toms (International Prostate Symptom Score [IPSS] ≥12; storage symptoms ≥4) were 
randomly assigned in a prospective, multicentered, and single-blind fashion to either 
the control group (alfuzosin 10 mg, once daily) or the combined group (alfuzosin 10 mg, 
once daily, and propiverine 10 mg, once daily) for 2 months. IPSS, maximal urinary 
flow rate (Qmax), and postvoid residual volume (PVR) were used to grade symptoms, 
side effects, and the impact on quality of life (QoL) at the start of the study and after 
1 and 2 months.
Results: There were no significant differences in patient background, including age, 
prostate size, Qmax, and PVR, between the control group and the combined group. In 
the combined group, the IPSS total score and the IPSS storage symptom score were 
significantly improved compared with the control group. The IPSS voiding symptom 
score, QoL, Qmax, and PVR did not differ significantly. There were no serious side ef-
fects in either group. 
Conclusions: Management with an α1-receptor antagonist combined with a low-dose 
anticholinergic improved the total score and storage symptom score of the IPSS com-
pared with α1-receptor antagonist only group without causing serious side effects. This 
initial combination medication can be considered an effective and safe treatment mo-
dality for LUTS/BPH patients with storage symptoms.
Key Words: Cholinergic antagonists; Propiverine; Prostatic hyperplasia
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial 
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.
Article History:
received 11 February, 2011
accepted 31 March, 2011
Corresponding Author:
Hyung Jee Kim
Department of Urology, Dankook 
University College of Medicine, San 
16-5, Anseo-dong, Cheonan 
330-715, Korea
TEL: +82-41-550-6630
FAX: +82-41-556-0524
E-mail: killtumor@yahoo.co.kr
INTRODUCTION
Although the symptoms of lower urinary tract symptoms/ 
benign prostatic hyperplasia (LUTS/BPH) are normally 
divided into storage symptoms and voiding symptoms, 52- 
84% of patients have overactive bladder symptoms [1,2]. 
Moreover, as a patient ages, the natural course increases 
the frequency of overactive bladder symptoms [3,4]. Tradi-
tional management of BPH focuses on voiding symptoms 
through surgeries like transurethral resection of the pro-Korean J Urol 2011;52:274-278
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TABLE 1. Baseline characteristics, IPSS, and QoL index in the 
two groups
Control group 
(n=77)
Combined group
(n=132)
p-value
Age (yr) 64.7±10.0 62.3±10.3 0.805
Prostate size (ml) 26.9±8.9 26.1±7.8 0.890
Qmax (ml/s) 15.1±8.4 14.7±7.8 0.810
PVR (ml)    44±37.7 41.7±31.8 0.769
IPSS
　Total 19.0±6.3 23.2±6.8 0.716
　Voiding 10.9±4.1 13.2±4.7 0.680
　Storage 8.1±3.4 10.0±2.8 0.591
QoL score 4.2±0.9 4.5±0.9 0.612
Qmax: maximal urinary flow rate, PVR: postvoid residual urine 
volume, IPSS: International Prostate Symptom Score, QoL: qual-
ity of life
state (TURP) or the use of medicines such as α1-receptor 
antagonists or 5-alpha reductase inhibitors. Even though 
voiding symptoms are alleviated after the use of medicines 
or TURP, storage symptoms continue for about 30% of pa-
tients [5-7]. Theoretically, in this circumstance, adminis-
tering anticholinergics would help to improve the LUTS/ 
BPH [8,9]. However, adding anticholinergics to patients 
with LUTS/BPH is not widely applied in clinical practice, 
because it could aggravate voiding symptoms, increase the 
risk of acute urinary retention, or increase adverse effects 
[1]. Also, as elderly patients receive medicines with more 
anticholinergic ingredients [10], there may be a greater 
chance of side effects and the severity of the side effects 
could increase, even though an accurate dosage of anti-
cholinergics can be safe for elderly patients who have a nor-
mal urinary flow rate and less residual urine. Even though 
many methods have been suggested to prevent the side ef-
fects of anticholinergics, such as beta-3 agonist [11], puri-
noreceptor antagonist [12], or COX inhibitor [13], these are 
still in the development phase, and the clinical trials of 
these medications are still in debate. The aim of this study 
was to evaluate the effect and safety of low-dose anti-
cholinergics combined with an α1-receptor antagonist in 
LUTS/BPH patients with the existence of storage symp-
toms to decrease the adverse effect of anticholinergics and 
to improve both the storage symptoms and the voiding 
symptoms.
MATERIALS AND METHODS
This prospective open-label, parallel-group, single-blinded, 
multicenter study was performed under Institutional Re-
view Board approval of every medical center that partici-
pated, and written informed consent was received from all 
patients. 
　Inclusion criteria were as follows: presence of LUTS/BPH 
with International Prostate Symptom Score (IPSS) ≥12 
and IPSS storage subscore ≥4. Patients with urinary re-
tention, postvoid residual urine (PVR) ≥200 ml, hydro-
nephrosis, renal impairment, intractable hematuria, pro-
state cancer, history of pelvic surgery, neurogenic bladder, 
urethral stricture, or chronic bacterial prostitis were ex-
cluded at the start of treatment. The maximal urinary flow 
rate (Qmax) was not considered as an inclusion criterion. 
Patients with a medical history of use of a 5ARI within 6 
months were also excluded. 
　Propiverine 10 mg was used as the low-dose anticholi-
nergic. Two hundred fifty men, aged 50 years or older, with 
LUTS/BPH were enrolled in this study and randomly as-
signed to either the control group (alfuzosin 10 mg, once 
daily) or the combined group (alfuzosin 10 mg, once daily, 
and propiverine 10 mg, once daily) for 2 months in a 2:3 ratio 
according to consultation with a statistician. The patients 
were randomized by use of a randomization table. 
　Before the medication was started, IPSS (total, voiding, 
and storage scores with QoL), age, blood pressure, comor-
bidity, combined medications, prostate size (by transrectal 
ultrasound), Qmax, PVR, and serum prostate-specific an-
tigen (PSA) were evaluated. After the groups had received 
medication for 1 month, we measured IPSS, Qmax, PVR, 
and side effects of anticholinergics. The same tests were 
executed at the end of the study.
　The primary endpoint was whether storage symptoms 
of the IPSS improved after medication for 8 weeks. The sec-
ondary endpoint was whether there was a reduction in ad-
verse effects, whether voiding symptoms were affected, 
and whether there was a decrease in Qmax. 
　All values are presented as the mean±standard deviation 
(SD). The significance of differences among groups was de-
termined by using Student’s t-test and repeated-measures 
ANOVA with differences considered significant at p＜0.05.
RESULTS 
Among the 250 subjects who were randomly assigned, 207 
subjects finished the study. The numbers in the control 
group and combined group were 77 and 132, respectively. 
There were no significant differences in the patient’s char-
acteristics, including age, prostate size, Qmax, and PVR, 
between the control group and the combined group (Table 
1). Although the total, voiding, and storage symptom scores 
of the IPSS were higher in the combined group than in the 
control group, the differences were not statistically sig-
nificant (p＞0.05 respectively) (Table 1). The total IPSS 
score of both groups was significantly improved after 2 
months of medication. The total IPSS score of the control 
group changed from 19.0±6.3 to 11.2±5.6, and that of the 
combined group changed from 23.2±6.8 to 14.9±4.7. The 
IPSS storage score of the control group changed from 8.1± 
3.4 to 4.7±2.3, and that of the combined group changed from 
10.0±2.8 to 6.0±2.2. The improvement in the IPSS voiding 
score and QoL was not significantly different between the 
two groups at 2 months (Fig. 1). However, compared with 
the control group, the combined group had significantly 
greater improvement at 2 months in the IPSS total and 
storage scores (p=0.031 and p=0.004, respectively) (Fig. 1).Korean J Urol 2011;52:274-278
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FIG. 1. Change from baseline to months 1 and 2 in IPSS total, void-
ing, and storage scores and quality of life index in the control and
combined groups. IPSS: International Prostate Symptom Score,
a: p＜0.05.
FIG. 2. Change in maximal flow rate (upper) and post-voided residual urine volume (lower) in the control and combined groups at each
time point. At the 0.05 level, the difference in the population means was not significantly different than the test difference. Data are
mean values and were analyzed by repeated-measures ANOVA.
TABLE 2. Reported adverse events during the medication period
Control group 
(n=77)
Combined group 
(n=132)
Voiding difficulty (%)
Dry mouth (%)
Dizziness (%)
1 (1.3)
1 (1.3)
1 (1.3)
6 (4.5)
2 (1.5)
1 (0.7)
　Qmax in uroflowmetry and PVR were improved in both 
groups at each time point, but were not significantly differ-
ent compared with the baseline data. The improvement in 
Qmax and PVR did not differ significantly between the two 
groups (Fig. 2). During the study there were nine cases of 
minor adverse events. However, no serious adverse events 
were reported. The control group had 3 cases (3.9%) and the 
combined group had 9 cases (6.8%) of side effects (Table 2). 
Patients who had voiding difficulty complained of postvoid 
tenesmus (2 cases), straining voiding (2 cases), hesitancy 
(1 case), and terminal dribbling (1 cases). None of these pa-
tients showed specific differences in baseline character-
istics, including age, prostate size, Qmax, and PVR. All side 
effects were mild and there were no cases of stopping medi-
cation because of side effects.
DISCUSSION
In theory, when voiding symptoms are the first priority in 
LUTS/BPH, an α1-receptor antagonist can be considered 
as a treatment of choice, and in the case of a large prostate, 
a 5-alpha reductase inhibitor can be added to reduce the 
volume of the prostate. When storage symptoms are the 
first priority in LUTS/BPH, combined therapy with an 
α1-receptor antagonist and an anticholinergic can be an 
appropriate choice. These medication therapies could the-
oretically improve both voiding and storage symptoms 
[8,9]. In practice, however, clinicians hesitate to adminis-
ter anticholinergics, especially to patients with severe ob-
structive symptoms or a large prostate. The use of anti-
cholinergics can make clinicians anxious because of the 
possibility of worsening existing voiding symptoms, in-
creasing residual urine, or even worse, causing urinary 
retention. Thus, most clinicians use an alpha-blocker first 
to ease the urinary symptoms and then use anticholinergics 
to improve the storage symptoms. As mentioned above, 
combined therapy from the beginning can lead to an increase 
in residual urine, which can be a bigger problem. However, 
even though an increase in residual urine is possible, it is 
not frequent enough to increase the risk of urinary re-
tention clinically. Moreover, it was reported recently that 
there is no urinary retention with administration of anti-
cholinergics alone [14-17].
　However, earlier published clinical demonstrations have 
not reflected the real clinical situation, because the testing 
involved very strict inclusion and exclusion criteria. In other 
words, the demonstrations excluded all patients with the 
risk factors that trigger acute urinary retention, such as se-
vere bladder outlet obstruction or a large amount of residual 
urine. Because there can be huge residual urine, or detrusor 
underactivity, or myogenic failure as a result of aging in a Korean J Urol 2011;52:274-278
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real-life practice, it is hard to compare the efficacy and safety 
of anticholinergics [18,19]. In addition, an analysis is needed 
of the side effects that reduce QoL, such as dry mouth or 
constipation, and consideration must be given to the chan-
ges in pharmacodynamics and pharmacokinetics and poly-
pharmacy of elderly patients.
　The incidence of dry mouth, a common side effect of anti-
muscarinic treatment, was reported by 24% of male blad-
der outlet obstruction patients treated with tolterodine 4 
mg [14]. Another study reported that the incidence was 
21% in patients taking a combination of tamsulosin and tol-
terodine 4 mg [15]. Combination treatment with propiver-
ine 20 mg and doxazosin 4 mg has been reported, and the 
results showed an incidence of dry mouth of 18.3% [16]. The 
incidence of dry mouth in our study was only 1.5%, which 
is quite lower than in other studies. This may have been 
the result of the low dose of propiverine or the low level of 
suspicion of the investigator. However, it is clear that a low 
dose of propiverine causes a low incidence of dry mouth and 
can increase patience compliance. Also, some evidence sug-
gests that nighttime dosing may reduce the incidence of dry 
mouth and other adverse events [20].
　The most severe side effects of anticholinergics related 
to urology are acute urinary retention and an increase in 
residual urine. The most frequent side effect is dry mouth, 
but constipation, dry eyes, confusion, constipation, somno-
lence, blurred vision, increased heart rate, angioedema, ar-
rhythmias, disorientation, hallucination, and convulsion 
can also occur [1]. The incident rates of these side effects 
increase as the patient ages. Elderly patients taking anti-
cholinergics have a lower metabolism and slower elimi-
nation of drugs, increased permeability in the blood-brain 
barrier, changes in the number and distribution of musca-
rinic receptors, and age-related deficits compared with 
younger patients [21]. Also, for nursing home patients, it 
is reported that 21% to 32% of patients take more than two 
drugs that have anticholinergic effects, 10% to 17% take 
more than three, and 5% take more than five [21,22]. Even 
though these facts address the need for control of the dosage 
of anticholinergics, few studies have been conducted on the 
effects of low-dose anticholinergics for patients with LUTS/ 
BPH. Moreover, in therapy for female overactive bladder 
(OAB), the ratio of stopping a normal dose of anticholiner-
gics because of side effects is quite high. This makes clini-
cians feel the need for a change in therapy practice [23-26]. 
We can infer that the ratio is higher in male overactive blad-
der patients with bladder outlet obstruction. Therefore, 
the objective of this research was to find methods to treat 
male overactive bladder that are based on alpha-blocker 
usage with maintenance of the effect of the alpha-blocker, 
a decrease in the side effects of anticholinergics, and im-
provement in the symptoms of LUTS/BPH.
　The average dose of propiverine is 20 mg once daily, and 
it can be used at doses up to 40 mg once daily. Accordingly, 
we prescribed propiverine 10 mg once daily as a low dose. 
The improvement in storage symptoms in the control group 
might have been due to the alpha-blocker. However, low- 
dose propiverine had only a little of the side effects of anti-
cholinergics and reduced the total score and storage symp-
tom score of the IPSS. The improvement in the voiding 
symptom score of the IPSS, Qmax, and PVR in the combined 
group did not differ significantly from the changes in the 
control group and the side effects remained slight. 
　This implies that low-dose propiverine is appropriate as 
a primary therapy for the storage symptoms of LUTS/BPH, 
especially in elderly patients. In this study, the IPSS score 
was the main inclusion criterion and Qmax was not consid-
ered as an inclusion criterion. Some of the subjects showed 
a relatively good maximal flow rate. However, it is not un-
common to find LUTS patients who have a good maximal 
flow rate but want to treat their LUTS. Also, the mean pros-
tate size of the included subjects was only 26 g, and the im-
provements in storage symptoms after medication may in-
crease voiding volume at the time of evaluating Qmax. 
These factors might have resulted in the marked improve-
ments in Qmax in this study. 
　This investigation had a limitation in that it was not a 
double-blinded study using a placebo. Therefore, the com-
bined group might have felt that they achieved more satis-
factory results because of the additional drug, propiverine, 
compared with the control group. Also, the follow-up period 
was only 8 weeks, which is relatively shorter than in usual 
studies. In future research, as Kaplan et al suggested, well- 
designed, large, double-blind, placebo-controlled, long-term 
randomized controlled trials are needed to assess the safe-
ty and efficacy of low-dose anticholinergics in LUTS/BPH 
[15].
CONCLUSIONS
According to this randomized study, alfuzosin with low- 
dose propiverine was superior to alfuzosin alone for IPSS 
total and storage scores in LUTS/BPH patients with stor-
age symptoms. The combination of an α1-receptor antago-
nist with a low-dose anticholinergic can be considered an 
effective and safe treatment modality from the start that 
does not result in more serious side effects in LUTS/BPH 
patients with storage symptoms.
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